Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing a novel class of peripherally acting kappa opioid agonist therapeutics with a primary focus for the treatment of pruritus and pain. The company’s fast paced environment meant it needed technology and processes that would support tight deadlines, complex protocol designs, and frequent mid-study changes. When Veeva approached Cara about Vault EDC, Cara had a phase I and a phase II study that would fit an early adopter program. With those first two studies, Veeva cut Cara’s standard build times by half.
As an early adopter, many of Cara’s requests and product ideas helped inform Veeva’s product roadmap and produce an EDC that offers a powerful reporting tool for operational insights and supports sponsor/CRO collaboration.